John T. Poirier

NYU Langone Health — United States

Medicine · Health Sciences

58h-index16.4kcitations415works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(230), Lung Cancer Treatments and Mutations(105), Radiopharmaceutical Chemistry and Applications(76), Neuroendocrine Tumor Research Advances(73), Cancer therapeutics and mechanisms(45)

Publications415 total

SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress
Nature Communications·2025Open Access
Cross-species analysis identifies genotype-driven vulnerabilities in lung adenocarcinoma
2025Open Access
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
npj Precision Oncology·2025· 3 citedOpen Access
An enhanced Eco1 retron editor enables precision genome engineering in human cells without double-strand breaks
Nucleic Acids Research·2025· 2 citedOpen Access
Imaging with [ <sup>89</sup> Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: A phase 1/2, first-in-human trial.
Journal of Clinical Oncology·2025
Deep Mutational Scanning Reveals EGFR Mutations Conferring Resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
2025
OA05.01 Deep Mutational Scanning Reveals Novel EGFR Mutations Conferring Resistance to Osimertinib and BLU-945
Journal of Thoracic Oncology·2025
A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist
PLoS Biology·2024· 12 citedOpen Access
An enhanced Eco1 retron editor enables precision genome engineering in human cells without double-strand breaks
2024· 2 citedOpen Access
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
The Lancet Oncology·2024· 37 citedOpen Access
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
UNC Libraries·2024Open Access
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer
Science Advances·2024· 52 citedOpen Access
228P SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGFβ signaling
ESMO Open·2024Open Access
A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist
2024· 1 citedOpen Access
First-in-human imaging with [ <sup>89</sup> Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate
2024· 4 citedOpen Access
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma
Nature Communications·2023· 20 citedOpen Access
EP13.06-04 Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers
Journal of Thoracic Oncology·2023
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Cell Reports·2023· 106 citedOpen Access
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer
2023· 4 citedOpen Access
A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.
Journal of Clinical Oncology·2023
page 1 of 21Next →

Frequent Co-authors

Charles M. Rudin(37), Elisa de Stanchina(10), Natasha Rekhtman(9), Pierre P. Massion(6), Viola Allaj(6), Eric E. Gardner(6), Caroline Dive(5), Julien Sage(5), Francisco J. Sánchez‐Rivera(5), André L. Moreira(5), Benjamin H. Lok(5), Triparna Sen(5), Scott W. Lowe(5), Christine L. Hann(5), Lauren A. Byers(4), Afshin Dowlati(4), David MacPherson(4), John D. Minna(4), Roman K. Thomas(4), William D. Travis(4)